This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D’Abronzo, F. H. Articles by Alexander, J. M. Search for Related Content PubMed PubMed Citation Articles by D’Abronzo, F. H. Articles by Alexander, J. M.

Mutational Analysis of Activin/Transforming Growth Factor-ß Type I and Type II Receptor Kinases in Human Pituitary Tumors¹

Neuroendocrine Unit, Departments of Medicine and Neurosurgery (B.S.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Anne Klibanski, M.D., Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, BUL457B, Boston, Massachusetts 02114-2696.

Genetic mutation or loss of activin/transforming growth factor-ß (TGFß) receptor function has been shown in human lymphoid, breast, and colorectal tumors as well as Hep2B and Mv1Lu cell lines. Although activin stimulates FSHß biosynthesis and secretion, a large percentage of human gonadotroph tumors have previously been demonstrated to be nonresponsive to characterized activin effects. This phenotype may be indicative of loss of functional cell surface receptors and/or intracellular signaling mediators of activin responses. Several studies examining the structure/function of type I and II receptors specific for ligands in the TGFß superfamily have delineated the critical regions for receptor intracellular kinase function. In the case of TGFß, inactivating mutations in these regions have been shown to render these receptors kinase deficient by a dominant negative phenotype and result in resistance to growth arrest. We therefore hypothesized that activin/TGFß cell surface receptors may act as tumor suppressors in human pituitary tumors, and that inactivating genetic mutations in the intracellular kinase region of this gene family may release pituicytes from normal growth suppression by activin through a similar mechanism. We used single stranded conformational polymorphism analysis to examine 2 intracellular regions required for type I receptor signaling by human Alk1–5 type I receptors as well as the entire coding region of 2 activin type II receptors and the TGFß type II receptor in 64 human pituitary tumors. A novel polymorphism was found in 45% of tumors at codon P117 of the ActRIIA gene and was used as a positive control for single stranded conformational polymorphism. One patient with a gonadotroph tumor had a confirmed A482V germline mutation in the Alk1 gene within kinase subdomains X–XI. No other mutations were detected in any tumor studied. These data suggest that somatic mutations within these intracellular kinase regions of type I/type II receptors are rare in human pituitary tumors.

This article has been cited by other articles:

				J. McDonald, F. Gedge, A. Burdette, J. Carlisle, C. J. Bukjiok, M. Fox, and P. Bayrak-Toydemir Multiple Sequence Variants in Hereditary Hemorrhagic Telangiectasia Cases: Illustration of Complexity in Molecular Diagnostic Interpretation J. Mol. Diagn., November 1, 2009; 11(6): 569 - 575. [Abstract] [Full Text] [PDF]

				S A Abdalla and M Letarte Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease J. Med. Genet., February 1, 2006; 43(2): 97 - 110. [Abstract] [Full Text] [PDF]

				S. van den Driesche, C. L. Mummery, and C. J.J. Westermann Hereditary hemorrhagic telangiectasia: an update on transforming growth factor {beta} signaling in vasculogenesis and angiogenesis Cardiovasc Res, April 1, 2003; 58(1): 20 - 31. [Abstract] [Full Text] [PDF]

				H. Chang, C. W. Brown, and M. M. Matzuk Genetic Analysis of the Mammalian Transforming Growth Factor-{beta} Superfamily Endocr. Rev., December 1, 2002; 23(6): 787 - 823. [Abstract] [Full Text] [PDF]

				C Olivieri, E Mira, G Delu, F Pagella, A Zambelli, L Malvezzi, E Buscarini, and C Danesino Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia J. Med. Genet., July 1, 2002; 39(7): e39 - 39. [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				D. C. Danila, W. J. Inder, X. Zhang, J. M. Alexander, B. Swearingen, E. T. Hedley-Whyte, and A. Klibanski Activin Effects on Neoplastic Proliferation of Human Pituitary Tumors J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1009 - 1015. [Abstract] [Full Text]